Leerink Partnrs Analysts Cut Earnings Estimates for Insulet

Insulet Co. (NASDAQ:PODD - Free Report) - Leerink Partnrs dropped their Q4 2024 earnings per share (EPS) estimates for shares of Insulet in a research report issued to clients and investors on Thursday, November 7th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings of $0.99 per share for the quarter, down from their previous forecast of $1.00. The consensus estimate for Insulet's current full-year earnings is $3.10 per share. Leerink Partnrs also issued estimates for Insulet's Q2 2025 earnings at $0.88 EPS, Q3 2025 earnings at $1.15 EPS, Q4 2025 earnings at $1.22 EPS, FY2027 earnings at $6.46 EPS and FY2028 earnings at $7.75 EPS.

Several other research firms have also weighed in on PODD. Canaccord Genuity Group lifted their price objective on Insulet from $236.00 to $269.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Piper Sandler lifted their price objective on Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Raymond James boosted their price target on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research report on Monday, October 14th. Sanford C. Bernstein initiated coverage on Insulet in a research report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price target on the stock. Finally, UBS Group boosted their price target on Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.27.

Insulet Trading Up 2.9 %

Shares of NASDAQ PODD traded up $7.70 during midday trading on Monday, hitting $275.70. The stock had a trading volume of 803,320 shares, compared to its average volume of 782,225. The company has a market capitalization of $19.33 billion, a price-to-earnings ratio of 47.23, a PEG ratio of 5.00 and a beta of 1.22. Insulet has a 1-year low of $156.00 and a 1-year high of $279.40. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The company has a fifty day moving average price of $232.01 and a 200 day moving average price of $204.48.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). The firm had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 21.22% and a return on equity of 30.29%. The business's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.38 earnings per share.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 58 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Insulet in the 2nd quarter valued at approximately $32,000. Venturi Wealth Management LLC increased its holdings in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 133 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 81 shares during the last quarter. Finally, CVA Family Office LLC increased its holdings in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock valued at $50,000 after acquiring an additional 145 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.